The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
Recruiting now
Conditions studied: Peritoneal Metastasis, Gastric Cancer
In brief
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
Key facts
- Study ID
- NCT06597526
- Run by
- Ruijin Hospital
- People needed
- 30
- Starts
- 2024-06-15
- Expected to finish
- 2029-05-31
- Last updated by the study team
- 2024-09-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
- Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
- Patients voluntarily enrolled in this study by signing an informed consent form
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
- Expected life expectancy ≥ 3 months
- Adequate organ and bone marrow function
- Willingness to adhere to the study protocol and follow-up programme
You may not qualify if…
- Signs of distant metastases other than peritoneal metastases at enrolment
- Pregnant or breastfeeding women.
- Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
- Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Where it is running
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.